Insider transactions

BAKER BROS. ADVISORS LP

CIK 1263508 · last filed 2026-07-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$2.41B
Companies
25
Total Filings
94
Lifetime Open-Market Net
$3.38B

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

BGNE price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
860 WASHINGTON STREET
3RD FLOOR
NEW YORK, NY 10014
Phone
(212) 339-5600
State of Incorporation
DE
Formerly Known As
BAKER BROS ADVISORS LLC (2003–2013)
Related Filers
Julian Baker — 591 joint filings, latest 2026-08-11
Felix Baker — 585 joint filings, latest 2026-08-11
Baker Bros. Advisors (GP) LLC — 555 joint filings, latest 2026-08-11
Baker Brothers Life Sciences LP — 525 joint filings, latest 2026-08-11
667, L.P. — 520 joint filings, latest 2026-08-11
14159, L.P. — 215 joint filings, latest 2019-10-03
INCYTE CORP — 96 joint filings, latest 2026-07-02
Baker Bros. Investments, L.P. — 81 joint filings, latest 2019-10-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KOD Director 15,316,021 $89.96 $1.38B $106.09M 5 2026-07-02
PRLD Director — $3.70 — $0 2 2026-04-22
BCYC Director 937,483 $3.65 $3.42M $0 1 2026-01-06
KALA 930 $0.18 $167 -$4.23M 1 2025-10-02
KYMR Director 534,134 $111.78 $59.71M $173.05M 2 2025-06-30
ACAD Director 39,468,841 $19.72 $778.33M $1.96B 10 2025-06-02
INCY Director 314,600 $113.47 $35.70M $1.09B 11 2025-04-02
IMCR Director 2,144,060 $31.04 $66.55M $143.96M 2 2025-03-19
BeOne Medicines Ltd. (BGNE) Delisted Director 136,517 $184.71 $25.22M -$1.48B 8 2024-12-10
MDGL Director 179,279 $434.40 $77.88M $135.10M 3 2024-03-25
Atreca, Inc. (BCEL) Delisted 2,971,128 $0.15 $445.7K -$442.3K 1 2023-10-23
TCRX Director — $0.19 — $0 1 2023-06-15
Seagen Inc. (SGEN) Delisted Director 42,989,787 $228.74 $9.83B $955.17M 9 2022-05-17
KNSA Director — $86.22 — $0 2 2020-07-02
Neurogene Inc. (NLTX) Delisted Director — $13.96 — $0 1 2019-10-15
IGM Biosciences, Inc. (IGMS) Delisted Director 2,883,204 $1.27 $3.66M $301.82M 1 2019-09-20
Aceragen, Inc. (IDRA) Delisted Director 253,701 $7.22 $1.83M $45.50M 4 2019-07-03
GENOMIC HEALTH INC (GHDX) Delisted Director 7,641,248 — — -$413.77M 10 2019-06-18
HOOKIPA Pharma Inc. (HOOK) Delisted 82,073 $1.15 $94.4K $50.00M 1 2019-04-23
Mirati Therapeutics, Inc. (MRTX) Delisted 10%+ Owner 2,372,355 $58.70 $139.26M $28.00M 2 2017-11-13
Neurogene Inc. (AQXP) Delisted Director 9,412,424 — — $170.50M 4 2017-05-09
BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted 10%+ Owner 43,476 $0.07 $3.3K $8.00M 1 2017-03-28
Invitae Corp (NVTA) Delisted 10%+ Owner 734,261 $0.09 $65.4K $17.60M 1 2016-11-18
BCRX 10%+ Owner 1,680,147 $7.89 $13.26M -$65.62M 3 2016-08-16
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Director 0 — — $158.62M 2 2015-06-23

Recent Filings · Page 7 of 10

94 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-09-08 INCY Buy (P) +700,000 $92.40M EDGAR
2017-08-14 BeOne Medicines Ltd. (BGNE) Delisted Buy (P) +1,232,392 $87.50M EDGAR
2017-06-16 — Buy (P) +8,093,730 $941.49M
2017-05-12 — Grant (A) +24,360 $0
2017-05-09 Neurogene Inc. (AQXP) Delisted Grant (A) — $0 EDGAR
2017-03-28 BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Buy (P) +666,664 $8.00M EDGAR
2017-01-09 Neurogene Inc. (AQXP) Delisted Buy (P) +1,592,248 $27.35M EDGAR
2016-11-21 BeOne Medicines Ltd. (BGNE) Delisted Buy (P) +12,323,465 $394.35M EDGAR
2016-11-18 Invitae Corp (NVTA) Delisted Buy (P) +2,933,332 $17.60M EDGAR
2016-11-03 Seagen Inc. (SGEN) Delisted Buy (P) +1,190,598 $67.18M EDGAR
Showing 61–70 of 94
Page 7 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.